Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

MK-677 does not meet efficacy endpoints in a phase II Alzheimer's disease study

Nov. 26, 2008

DepoMed enters into exclusive license agreement with Solvay for DM-1796

Nov. 26, 2008

ChemDiv and Avineuro extend collaboration in Alzheimer's disease

Nov. 26, 2008

Neuromed completes enrollment for phase III trial of NMED-1077 in chronic low back pain

Nov. 26, 2008

Hemispherx enters major contract with Lovelace Respiratory Research Institute

Nov. 26, 2008

Xenazine tablets available in U.S. for chorea associated with HD

Nov. 25, 2008

Valdoxan receives CHMP positive opinion for major depressive disorder

Nov. 25, 2008

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

Nov. 25, 2008

EMEA recommends the suspension of the marketing authorization of Ionsys

Nov. 25, 2008

New neuropsychiatric agents reported

Nov. 25, 2008

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...